Uphill Climb For Gedeon Richter's Cariprazine After Delayed EU OK

Gedeon Richter has finally had its antipsychotic cariprazine approved in the EU for treating schizophrenia - but its delay to market could dampen demand for the drug unless it can differentiate itself from rivals.

Schizophrenia
Gedeon Richter's Cariprazine Wins EU OK For Treating Schizophrenia • Source: Shutterstock

Gedeon Richter PLC 's antipsychotic cariprazine – which has EU approval following a positive regulatory assessment in May - is expected to start launching across the EU on a country by country basis from mid-2018 when pricing and reimbursement has been finalized, analysts say.

But to drive its uptake, Hungary-based Gedeon and its European market partner Recordati Industria Chimica & Farmaceutica SPA of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip